Boston Scientific Corporation vs Iris Energy Limited — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Iris Energy Limited trades at $39.17 (market cap $13.80B). The key difference: Boston Scientific Corporation is far larger — about 4.8× Iris Energy Limited's market cap, and Iris Energy Limited is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | IREN | |
|---|---|---|
Market Cap | $66.37B | $13.80B |
Sector | Health | Energy |
52-Week High | $108.14 | $76.41 |
52-Week Low | $42.63 | $15.40 |
Enterprise Value | $75.94B | $15.55B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
IREN trades at $38.98, down 5.18% on the day, amid a bearish technical signal and recent earnings misses. The company is transitioning from Bitcoin mining to AI infrastructure, showing strong revenue growth projections for 2026 ($757M) and a net income margin improvement to 20.87%. However, negative ROE and ROA highlight profitability challenges. Analyst consensus remains bullish with a $79.11 price target, but high valuation ratios (P/E 50.14, P/S 14.99) suggest premium pricing.
The outlook hinges on successful execution of AI cloud expansion, with key risks including competitive pressures from Meta's cloud ambitions and operational scalability. Investors face a high-risk, high-reward scenario, balancing analyst optimism against technical weakness and recent stock volatility. Near-term catalysts include potential contracts and capacity milestones, but misses on earnings expectations warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →